Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Carlsmed (NASDAQ:CARL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.
Volatility and Risk
Vivos Therapeutics has a beta of 6.37, meaning that its stock price is 537% more volatile than the S&P 500. Comparatively, Carlsmed has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.
Institutional and Insider Ownership
26.4% of Vivos Therapeutics shares are held by institutional investors. 1.4% of Vivos Therapeutics shares are held by insiders. Comparatively, 12.9% of Carlsmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Vivos Therapeutics and Carlsmed”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.10 | -$21.17 million | ($1.90) | -0.05 |
| Carlsmed | $50.51 million | 7.95 | -$29.63 million | ($1.43) | -10.29 |
Vivos Therapeutics has higher earnings, but lower revenue than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Vivos Therapeutics and Carlsmed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Carlsmed | 1 | 1 | 4 | 0 | 2.50 |
Vivos Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 3,144.50%. Carlsmed has a consensus price target of $19.50, indicating a potential upside of 32.56%. Given Vivos Therapeutics’ higher possible upside, equities analysts plainly believe Vivos Therapeutics is more favorable than Carlsmed.
Profitability
This table compares Vivos Therapeutics and Carlsmed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
| Carlsmed | -57.42% | -38.06% | -28.96% |
Summary
Carlsmed beats Vivos Therapeutics on 9 of the 13 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.
About Carlsmed
Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients. Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
